MEDICAL POLICY – 2.01.526

Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders

Effective Date: Dec. 1, 2018
Last Revised: Nov. 21, 2018
Replaces: 2.01.50

RELATED MEDICAL POLICIES:
7.01.20 Vagus Nerve Stimulation

Select a hyperlink below to be directed to that section.

POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING
RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | APPENDIX | HISTORY

∞ Clicking this icon returns you to the hyperlinks menu above.

Introduction

Transcranial is a word that means passing through the skull. Transcranial magnetic stimulation is a treatment in which magnetic pulses travel through the skull and into the areas of the brain involved in mood control and depression. For this treatment, an electromagnetic coil is placed on the scalp. This coil creates magnetic fields that turn on and off very fast. The magnetic fields then travel into the brain, but only a small distance. As the pulses travel, they produce very weak electrical currents. It’s believed that these currents stimulate cells that release neurotransmitters like serotonin and dopamine. Transcranial magnetic stimulation can be used for certain types of depression when other treatments haven’t worked. This policy describes when transcranial magnetic stimulation may be medically necessary.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.
<table>
<thead>
<tr>
<th>Disorder</th>
<th>Medical Necessity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Major depressive disorder</strong></td>
<td>Transcranial magnetic stimulation (TMS) of the brain may be considered medically necessary for the treatment of Major Depressive Disorder (unipolar depression) when the patient is at least 18 years old, is experiencing a current episode of moderate to severe depression, and one of the following criteria are met:</td>
</tr>
<tr>
<td></td>
<td>• Failure of at least 4 different antidepressant medication trials, from at least 2 different classes, at adequate dose and duration or due to intolerable side effects</td>
</tr>
<tr>
<td></td>
<td><strong>OR</strong></td>
</tr>
<tr>
<td></td>
<td>• Failure of at least 3 different antidepressant medication trials, from at least 2 different classes, at adequate dose and duration or due to intolerable side effects, plus failure with the addition of an augmenting agent (lithium, thyroid medication, second generation antipsychotics, buspirone, stimulants) to at least one of the antidepressants <strong>OR</strong></td>
</tr>
<tr>
<td></td>
<td>• A positive clinical response to a previous course of treatment with TMS</td>
</tr>
<tr>
<td><strong>Standard repetitive transcranial magnetic stimulation (aka superficial transcranial magnetic stimulation), and deep transcranial magnetic stimulation, may be considered medically necessary when the criteria above are met.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Major depression as a component of bipolar disorder</strong></td>
<td>Transcranial magnetic stimulation (TMS) of the brain may be considered medically necessary for the treatment of bipolar depression (Major Depression as a component of Bipolar Disorder) when the patient is at least 18 years old, is experiencing a current episode of moderate to severe depression, and one of the following criteria are met:</td>
</tr>
<tr>
<td></td>
<td>• Failure of trials of at least 2 different medications with established effectiveness for bipolar depression (Latuda/lurasidone, lithium, Lamictal/lamotrigine, Seroquel regular/quetiapine regular or XR, or Symbyax/olanzapine-fluoxetine combination), at adequate dose and duration or due</td>
</tr>
</tbody>
</table>
## Disorder

<table>
<thead>
<tr>
<th>Medical Necessity</th>
</tr>
</thead>
<tbody>
<tr>
<td>to intolerable side effects</td>
</tr>
<tr>
<td>OR</td>
</tr>
<tr>
<td>• A positive clinical response to a previous course of treatment with TMS</td>
</tr>
</tbody>
</table>

Standard repetitive transcranial magnetic stimulation (aka superficial transcranial magnetic stimulation), and deep transcranial magnetic stimulation, may be considered medically necessary when the criteria above are met.

### Other Disorders/Other Types of TMS

<table>
<thead>
<tr>
<th>Investigational</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other psychiatric/ neurologic disorders Transcranial magnetic stimulation (TMS) of the brain is considered investigational as a treatment for all other psychiatric and neurologic disorders.</td>
</tr>
<tr>
<td>Other types of TMS Other types of TMS, including synchronized TMS, intermittent TMS, continuous TMS, low field magnetic stimulation, and theta burst stimulation, are considered investigational.</td>
</tr>
</tbody>
</table>

### Additional Information

**Standard repetitive transcranial magnetic stimulation (TMS) treatment consists of the following:**

- A course of 30 treatments over 6-7 weeks, followed by a 6 treatment taper over 2-3 weeks. The first treatment session may include treatment planning, cortical mapping, and initial motor threshold determination; 1-2 sessions may include motor threshold re-determination during the course of treatment with TMS.
- The medical necessity of more than one session that includes treatment planning, cortical mapping, and initial motor threshold determination is determined on a case-by-case basis.
- The medical necessity of more than two sessions that include motor threshold re-determination is determined on a case-by-case basis.
- The medical necessity of continued treatment with TMS after 30 treatments due to partial resolution of acute symptoms is determined on a case-by-case basis.

**Deep transcranial magnetic stimulation (TMS) treatment consists of the following:**

- A course of 20 treatments over 4 weeks, followed by a continuation phase of 2 treatments
Additional Information

weekly over 12 weeks, for a total of 44 treatments. The first treatment session may include treatment planning, cortical mapping, and initial motor threshold determination; 1-2 sessions may include motor threshold re-determination during the course of treatment with TMS.

- The medical necessity of more than one session that includes treatment planning, cortical mapping, and initial motor threshold determination is determined on a case-by-case basis.
- The medical necessity of more than two sessions that include motor threshold re-determination is determined on a case-by-case basis.
- The medical necessity of continued treatment with TMS after 44 treatments due to partial resolution of acute symptoms is determined on a case-by-case basis.

The medical necessity of TMS for patients younger than 18 years old is determined on a case-by-case basis.

The medical necessity of accelerated TMS (two treatments/day instead of one treatment/day, with the same total number of treatments, so as to complete treatment in ½ of the usual period of time) is determined on a case-by-case basis.

The medical necessity of an abbreviated (“mini-intensive”) or full repeat course of TMS due to symptom recurrence, exacerbation, or relapse is determined on a case-by-case basis.

The medical necessity of booster TMS treatments is determined on a case-by-case basis.

The medical necessity of maintenance treatment with TMS is determined on a case-by-case basis.

The medical necessity of continued TMS or of a repeat course of TMS when there was inadequate or no improvement during the initial course of TMS is determined on a case-by-case basis.

The medical necessity of sessions that include treatment planning, cortical mapping, and initial motor threshold determination, or sessions that include motor threshold re-determination, as part of continued TMS, repeat TMS, booster TMS treatments, or TMS maintenance treatment, is determined on a case-by-case basis.

Contraindications to TMS

- Vagus nerve stimulator leads in the carotid sheath
- Other implanted stimulators controlled by or that use electrical or magnetic signals
- Conductive, ferromagnetic, or other magnetic-sensitive metals implanted or embedded in the head or neck within 30cm of where the rTMS coil will be placed, except for dental fillings
- Current psychotic symptoms
Contraindications to TMS

- Acute or chronic psychotic disorder, including Schizophrenia, Schizoaffective Disorder, and Schizophreniform Disorder
- Seizure disorder or a history of a seizure disorder except for a history of isolated febrile seizures or ECT-induced seizures
- Current substance abuse
- Severe dementia
- Any condition with increased intracranial pressure
- Significant comorbid personality disorder or personality disorder features

Documentation Requirements

The patient’s medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following:

- Diagnosis
- Severity of symptoms
- Brief history of the diagnosis
- Medication trials, including the outcome of the trial for each medication
- Age of patient
- Contraindications, if any, to TMS
- CPT codes and the number of sessions for each CPT code

Coding

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td></td>
</tr>
<tr>
<td>90867</td>
<td>Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management</td>
</tr>
<tr>
<td>90868</td>
<td>Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session</td>
</tr>
<tr>
<td>90869</td>
<td>Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management</td>
</tr>
</tbody>
</table>

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).
Definition of Terms

Clinical response: Improvement of 50% or more in the Hamilton Depression Rating Scale

Remission: Score of 7 or less on the Hamilton Depression Rating Scale

Evidence Review

Description

Transcranial magnetic stimulation (TMS) is a non-invasive method of delivering electrical stimulation to the brain. A magnetic field is delivered through the skull, where it induces electric currents that affect neuronal function. Repetitive TMS (rTMS) is being evaluated as a treatment of depression and other psychiatric/neurologic brain disorders.

Background

Transcranial magnetic stimulation (TMS) was first introduced in 1985 as a new method of noninvasive stimulation of the brain. The technique involves placement of a small coil over the scalp; a rapidly alternating current is passed through the coil wire, producing a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex. TMS was initially used to investigate nerve conduction; for example, transcranial magnetic stimulation over the motor cortex will produce a contralateral muscular-evoked potential. The motor threshold, which is the minimum intensity of stimulation required to induce a motor response, is empirically determined for each individual by gradually increasing the intensity of stimulation. The stimulation site for treatment is usually 5 cm anterior to the motor stimulation site.

Interest in the use of transcranial magnetic stimulation as a treatment for depression was augmented by the development of a device that could deliver rapid, repetitive stimulation. Imaging studies had showed a decrease in activity of the left dorsolateral prefrontal cortex (DLPFC) in depressed patients, and early studies suggested that high frequency (e.g., 5–10 Hz)
TMS of the left DLPFC had antidepressant effects. Low frequency (1–2 Hz) stimulation of the right DLPFC has also been investigated. The rationale for low frequency TMS is inhibition of right frontal cortical activity to correct the interhemispheric imbalance. A combination approach (bilateral stimulation) or deep stimulation with an H1 coil, are also being explored. In contrast to electroconvulsive therapy, transcranial magnetic stimulation does not require anesthesia and does not induce a convulsion.

Repetitive transcranial magnetic stimulation (rTMS) is also being tested as a treatment for a variety of other disorders including alcohol dependence, Alzheimer disease, neuropathic pain, obsessive-compulsive disorder (OCD), post-partum depression, depression associated with Parkinson’s disease, stroke, posttraumatic stress disorder, panic disorder, epilepsy, dysphagia, Tourette’s syndrome, schizophrenia, migraine, spinal cord injury, fibromyalgia, and tinnitus (see Related Policies). In addition to the potential for altering interhemispheric imbalance, it has been proposed that high frequency rTMS may facilitate neuroplasticity.

**Depression**

Over the last decade, there has been a trend to increase the intensity, trains of pulses, total pulses per session, and number of sessions. Unless otherwise indicated in the trials described next, stimulation was set at 100% to 120% of motor threshold, clinical response was defined as an improvement of 50% or more on the Hamilton Rating Scale for Depression (HAM-D), and remission was considered to be a score of 7 or less on the HAM-D. Refer to the 2009 meta-analysis by Schutter for a summary of study characteristics and stimulation parameters used in trials conducted prior to 2008.2

The Blue Cross and Blue Shield Technology Evaluation Center (TEC) published an assessment of repetitive TMS (rTMS) for depression in 2009, 2011 and 2013. These TEC Assessments concluded that the available evidence did not permit conclusions regarding the effect of TMS on health outcomes. Limitations of the evidence included:

- Equivocal efficacy in the largest sham-controlled trial of TMS,
- Uncertain clinical significance of the short-term anti-depressant effects found in meta-analyses, which are also at high risk of bias due to the inclusion of numerous small trials and potential for publication bias,
- Limited evidence beyond the acute period of treatment, and
Lack of comparison with standard therapy (a second course of antidepressant therapy) in the population for whom TMS is indicated (patients who have failed one 6-week course of antidepressant medication).

The Agency for Healthcare Research and Quality (AHRQ) published a comparative effectiveness review on nonpharmacologic interventions for treatment-resistant depression (TRD) in adults in 2011. Findings for the key questions (KQ) of the review follow.

Efficacy of Nonpharmacologic Interventions Against Other Nonpharmacologic Interventions (KQ 1a)

**Direct Evidence**

The available head-to-head literature concerning the efficacy of the nonpharmacologic interventions for Tier 1 TRD was limited to two fair trials (both in major depressive disorder [MDD]-only populations). One compared ECT and rTMS, and the other compared ECT and ECT plus rTMS. They showed, with low strength of evidence, no differences between treatment options for depressive severity, response rates, and remission rates. No trial involved a direct comparison of psychotherapy with another nonpharmacologic intervention.

**Indirect Evidence**

Identified trials that compared a nonpharmacologic intervention, generally rTMS, VNS [vagus nerve stimulation], or psychotherapy, with a control or sham procedure in Tier 1 populations (ie, patients had 2 or more prior treatment failures with medications). The number of these trials with the same or similar control group was very small, so they could not pool them quantitatively. They assessed the potential benefits of nonpharmacologic interventions versus controls by calculating mean changes in depressive severity, relative risks of response, and relative risks of remission.

rTMS was beneficial relative to controls receiving a sham procedure for all 3 outcomes (severity of depressive symptoms, response rate, remission rate). rTMS produced a greater decrease in depressive severity (high strength of evidence). Specifically, rTMS averaged a decrease in depressive severity measured by the Hamilton Rating Scale for Depression (HAM-D) of more than 5 points relative to sham control, and this change meets the minimum threshold of the 3-point HAM-D difference that is considered clinically meaningful. Response rates were greater with rTMS than sham (also high strength of evidence); those receiving rTMS were more than
three times as likely to achieve a depressive response as patients receiving a sham procedure. Finally, rTMS was also more likely to produce remission than the control procedure (moderate strength of evidence); patients receiving rTMS were more than six times as likely to achieve remission as those receiving the sham.

Efficacy of Nonpharmacologic Interventions Compared With Antidepressant Pharmacotherapies (KQ 1b)

Direct Evidence

No direct evidence was identified for rTMS.

Maintenance of Remission or Prevention of Relapse (KQ 2)

Direct Evidence

With respect to maintaining remission (or preventing relapse), there were no direct comparisons involving ECT, rTMS, VNS, or CBT.

Maintenance of Remission or Prevention of Relapse (KQ 2)

Direct Evidence

With respect to maintaining remission (or preventing relapse), there were no direct comparisons involving ECT, rTMS, VNS, or CBT.

Indirect Evidence

Three fair trials compared rTMS with a sham procedure and found no significant differences. However, too few patients were followed during the relapse prevention phases in two of the three studies, and patients in the third received a co-intervention providing insufficient evidence for a conclusion.
AHRQ Author’s Conclusions

The evidence review suggests that comparative clinical research on nonpharmacologic interventions in a TRD population is early in its infancy, and many clinical questions about efficacy and effectiveness remain unanswered. Interpretation of the data is substantially hindered by varying definitions of TRD and the paucity of relevant studies. The greatest volume of evidence is for ECT and rTMS. However, even for the few comparisons of treatments that are supported by some evidence, the strength of evidence is low for benefits, reflecting low confidence that the evidence reflects the true effect and indicating that further research is likely to change our confidence in these findings. This finding of low strength is most notable in two cases: ECT and rTMS did not produce different clinical outcomes in TRD, and ECT produced better outcomes than pharmacotherapy. No trials directly compared the likelihood of maintaining remission for nonpharmacologic interventions. The few trials addressing adverse events, subpopulations, subtypes, and health-related outcomes provided low or insufficient evidence of differences between nonpharmacologic interventions. The most urgent next steps for research are to apply a consistent definition of TRD, to conduct more head-to-head clinical trials comparing nonpharmacologic interventions with themselves and with pharmacologic treatments, and to delineate carefully the number of treatment failures following a treatment attempt of adequate dose and duration in the current episode.

High frequency rTMS of the left DLPFC for Treatment-Resistant Depression (TRD)

There is a large body of evidence for the use of rTMS in the treatment of depression. The largest study (23 study sites) to date is included in the meta-analysis was a double blind multicenter trial with 325 TRD patients randomized to daily sessions of high frequency active or sham rTMS (Monday to Friday for 6 weeks) of the left dorsolateral prefrontal cortex (DLPFC). Treatment-resistant depression was defined as failure of at least one adequate course of antidepressant treatment. Patients had failed an average of 1.6 treatments in the current episode, with approximately half of the study population failing to benefit from at least 2 treatments. Loss to follow-up was similar in the 2 groups, with 301 (92.6%) patients completing at least one post-baseline assessment and an additional 8% of patients from both groups dropping out before the 4-week assessment. Intent-to-treat (ITT) analysis showed a trend favoring the active rTMS group in the primary outcome measure (2 points on the Montgomery-Asberg Depression Rating Scale [MADRS]; \( p = 0.057 \)) and a modest (2-point) but significant improvement over sham treatment on the HAM-D. The authors reported that after 6 weeks of treatment the subjects in
the active rTMS group were more likely to have achieved remission than the sham controls (14% vs. 5% respectively), although this finding is limited by loss-to-follow-up.

In 2010, George et al. reported a randomized sham-controlled trial that involved 190 patients treated with left-prefrontal rTMS. This was a multi-centered study involving patients with a moderate level of treatment resistance. The response rate using an ITT analysis was 14% for rTMS and 5% for sham (p=0.02). In this study, the site for stimulation was determined through pre-treatment magnetic resonance imaging (MRI). In a 3-week, open-label, follow-up phase of the study in which all patients received active therapy but remained masked to their original treatment arm, the remission rates rose to 30.2% in the originally active group and 29.6% in the original sham group.

Another randomized sham-controlled double-blind trial was conducted in 68 patients who had failed at least 2 courses of antidepressants. Three patients in each group did not complete the 15 treatment sessions or were excluded due to a change in medication during treatment, resulting in 91% follow-up. Independent raters found a clinical response in 31% (11 of 35) of the active rTMS patients and 6% (2 of 33) of the sham group. The average change in HAM-D was 7.8 for the active group and 3.7 for the control group. The Beck Depression Inventory (BDI) decreased by 11.3 points in the active rTMS group and 4.8 points in controls. Remission was observed in 7 patients (20%) in the active rTMS group and 1 patient (3%) in the control group. Regarding effectiveness of blinding; 15% of subjects in each group guessed that they were receiving active TMS after the first session. After the 15th session, 58% of the rTMS group and 43% of the sham group guessed that they had received active TMS; responders were more likely than non-responders (85% vs. 42%) to think that they had received the active treatment. The 11 responders were treated with antidepressant medication and followed for 6-months. Of these, 1 was lost to follow-up, 5 (45%) relapsed, and 5 (45%) did not relapse.

Rossini and colleagues randomized 54 patients who had failed at least two adequate courses of antidepressants to sham control or active rTMS at 80% or 100% of motor threshold (MT) for 10 sessions over a 2-week period. Double-blind evaluation found an intensity-dependent response with 6% (1 of 16) of the sham, 28% (5 of 18) of the 80% MT, and 61% (11 of 18) of the 100% MT groups showing improvement of 50% or more over a 5-week evaluation. All of the patients reported that they were unaware of the differences between sham and active stimulation.

In a 2008 report, Mogg et al. randomized 59 patients with major depression who had failed at least one course of pharmacotherapy for the index depressive episode. In this study population, 78% of the patients had failed 2 treatment courses and 53% had failed 3. The sham coil, which was provided by Magstim, was visually identical to the real coil and made the same clicking sound, but did not deliver a magnetic field to scalp or cortex. Blinded assessments were
measured 2 days after the 5th and final (tenth) sessions (97% follow-up), with additional assessments at 6 weeks (90% follow-up) and 4 months (83% follow-up). The mean group difference was estimated to be 0.3 points in HAM-D scores for the overall analysis. Interpretation of this finding is limited since 7 sham patients (23%) were given a course of real rTMS after the 6-week assessment and analyzed as part of the sham group in the ITT analysis. The study was powered to detect a difference of 3.5 points in the HAM-D between the active and sham groups, and the 2.9 point group difference observed at the end-of-treatment was not significant. A higher percentage of patients in the active rTMS group achieved remission criteria of 8 points or less on the HAM-D (25% vs. 10% control), and there was a trend for more patients to achieve clinical response in the active rTMS group (32% vs. 10%, p = 0.06). All of the 12 patients who met the criterion for clinical response (9 active and 3 sham) thought that they had received real rTMS, with more patients in the active group (70%) than the sham group (38%) guessing that they had received the real treatment. Interpretation of this finding is also limited, since the reason the subjects guessed that they had active treatment was not reported, and the subjects were not asked to guess before they began to show a clinical response.

A small double-blind randomized trial from 2009 suggests that specific targeting of Brodman areas 9 and 46 may enhance the anti-depressant response compared with the standard targeting procedure, i.e., measuring 5 cm anterior from the motor cortex. Fifteen-one patients who had failed at least two 6-week courses of antidepressant medication (average 5.7 failed courses) were randomized to a standard localization procedure or to structural magnetic resonance imaging (MRI)-aided localization for 3 weeks (with one-week extension if > 25% reduction on the MADRS). Six patients in the targeted group and 10 in the standard group withdrew due to lack of response. A single patient in the targeted group and 5 in the standard group withdrew for other reasons, resulting in 17 patients in the targeted group and 12 in the standard group continuing for the full 4 weeks of treatment. To adjust for the imbalance in discontinuation rates, a mixed model statistical analysis was used. There was a significant difference between the groups in the overall mixed model analysis, and planned comparisons showed significant improvement in MADRS scores for the targeted group at 4 weeks. Response criteria were met by 42% of the targeted group and 18% of the standard group. Remission criteria were met by 30% of the targeted group and 11% of the standard group. Although encouraging, additional trials with a larger number of subjects are needed to evaluate this procedure.

Comparison with ECT

Several studies have compared the outcomes of rTMS with those from electroconvulsive therapy. In one study, 40 patients with nonpsychotic major depression were treated over the
course of 1 month (20 total sessions) and evaluated with the HAM-D, in which a response was defined as a 50% decrease with a final score of less than or equal to 10. There was no difference in response rate between the 2 groups; 12 of 20 responded in the electroconvulsive therapy group compared to 11 of 20 in the magnetic stimulation group. A United Kingdom National Institute for Health Research health technology assessment compared efficacy and cost-effectiveness of rTMS and electroconvulsive therapy. Forty-six patients who had been referred for electroconvulsive therapy were randomly assigned to either electroconvulsive therapy (average of 6.3 sessions) or a 15-day course (5 treatments per week) of rTMS of the left DLPFC. Electroconvulsive therapy resulted in a 14-point improvement in the HAM-D and a 59% remission rate. Repetitive TMS was less effective than electroconvulsive therapy (5-point improvement in HAM-D and a 17% remission rate). Another study reported no significant difference between electroconvulsive therapy and rTMS in 42 patients with TRD; however, response rates for both groups were low. The number of remissions (score of 7 or less on the HAM-D) totaled 3 (20%) for electroconvulsive therapy and 2 (10%) for rTMS.

A 2013 systematic review by Berlim et al identified 7 RCTs with a total of 294 patients that directly compared rTMS and ECT treatment for patients with depression. After an average of 15.2 sessions of high-frequency rTMS over the left DLPFC, 33.6% of patients were classified as remitters. This compared with 52% of patients who were classified as remitters following an average of 8.2 ECT sessions. The pooled odds ratio was 0.46, indicating a significant difference in outcome favoring ECT. There was no significant difference in dropout rates for the 2 treatments.

Deep TMS of the Left Dorsolateral Prefrontal Cortex for Treatment-Resistant Depression

The randomized controlled trial leading to 510k clearance of the Brainsway deep TMS system was conducted at 20 centers in the U.S. (n=13), Israel (n=4), Germany (n=2), and Canada (n=1). The study included 229 patients with major depressive disorder who had not received benefit from 1 to 4 antidepressant trials or were intolerant to at least 2 antidepressant treatments. Per protocol analysis, which excluded 31 patients who did not receive adequate TMS treatment and 17 patients who did not meet the inclusion/exclusion criteria, showed a significant benefit for both response rate (38.4% vs 21.4%) and remission rate (32.6% vs 14.6%). Modified intent-to-treat analysis, which excluded the 17 patients who did not meet the inclusion/exclusion criteria, showed a significant benefit in both response rate (37% vs 22.8%) and remission rate (30.4% vs 15.8%). At the end of the maintenance period (16 week follow-up), the response rate remained significantly improved by deep TMS. Remission rates were not reported. Intent-to-treat analysis found no significant benefit of treatment at 4 or 16 weeks.
Low frequency rTMS of the right DLPFC or Bilateral Stimulation for Treatment-Resistant Depression (TRD)

Fitzgerald et al. randomized 60 patients who had failed a minimum of at least 2 six-week courses of antidepressant medications into one of 3 groups; high frequency left rTMS, low frequency right rTMS, or sham stimulation over 10 sessions. All patients who entered the study completed the double-blind randomized phase, which showed no difference between the two active treatments (left: 13.5% reduction; right: 15% reduction) and greater improvements in the MADRS scores compared to the sham group (0.76% reduction). Only 1 patient achieved 50% improvement during the initial 2 weeks. Then, only the subjects who showed at least 20% improvement at the end of the 10 sessions (15 active and 2 sham) continued treatment. Patients who did not respond by at least 20% were switched to a different active treatment. From week 2 to week 4 there was greater improvement in the low frequency right rTMS group compared with the high frequency left rTMS group (39% vs. 14% improvement in MADRS, respectively). Seven patients (18% of 40) showed a clinical response of greater than 50% by the end of the 4 weeks.

In a subsequent study Fitzgerald and colleagues randomized 50 patients with TRD to sequential bilateral active or sham rTMS. After 2 weeks of treatment, 3 subjects had dropped out of the sham treatment group and there was a slight but non-significant improvement favoring the active group for the MADRS (26.2 vs. 30.9, respectively) and the BDI (18.3 vs. 21.6, respectively). At this time point, 60% of subjects receiving active rTMS and 50% of subjects receiving sham treatment guessed that they were in the active group. The clinical response was reported by subjects as the major reason for their guess, with 11 of 13 responders (9 active and 2 sham) guessing that they were in the active group. As in the earlier study, only the subjects who showed at least 20% improvement at the end of each week continued treatment. Treatment on week 3 was continued for 15 subjects in the active group and 7 subjects in the sham group. By week six, 11 subjects in the active rTMS remained in the study, with no control subjects remaining. Final ratings for the 11 subjects who continued to respond through week 6 were 8.9 on the MADRS and 9.2 on the BDI.

Another multicenter double blind trial randomized 130 patients with treatment-resistant depression to 5 sessions per week of either 1- or 2-Hz rTMS over the right DLPFC. Sixty-eight patients (52%) completed 4 weeks of treatment; there was an approximate 30% improvement in depression scales, with no differences between the 1- or 2-Hz groups. Due to the potential for placebo effects for this type of intervention, the absence of a sham control group limits interpretation.
A small randomized, sham-controlled trial was published in 2010 that involved either right or left rTMS in 48 patients with TRD. Overall reductions in the HAM-D-24 from baseline to 3 months were not significantly different between rTMS and sham treatment groups. In this small study, right cranial stimulation was significantly more effective than left cranial stimulation (sham or rTMS).

**rTMS as an Adjunctive Treatment for Moderate to Severe Depression**

Schutter conducted a meta-analysis of 30 double-blind randomized sham-controlled trials (1,164 patients) of high frequency rTMS over the left DLPFC in patients with major depression. The pooled weighted mean effect size for treatment was calculated with Hedges’ g, a standardized mean difference that adjusts for sampling variance, to be 0.39 (95% confidence interval 0.25-0.54), which is considered moderate. For 27% of the population rTMS was used as a primary/adjunctive treatment; 3 trials were included that used rTMS as a primary/adjunctive treatment for depression and enrolled more than 40 subjects. Repetitive TMS has also been examined in patients with clinical evidence of cerebrovascular disease and late-life depression.

A 2012 study examined the efficacy of ultra-high frequency (30Hz) rTMS over the left prefrontal cortex in moderate to severely depressed patients who were taking medication. Sham treatment consisted of low frequency stimulation to the left prefrontal cortex. No benefit of rTMS was found to improve performance on the trail-making test, which covaried with improvement of psychomotor retardation.

Additional research on whether adjunctive rTMS can improve response to pharmacologic treatment as a first-line therapy is also needed.

**Maintenance Therapy**

Demirtas-Tatlidede et al. reported durability of the antidepressant response to rTMS and efficacy of retreatment for relapses in a prospective series of 16 patients. Patients who initially had clinically significant antidepressant responses to rTMS were enrolled in the study and followed for 4 years. During this period there were a total of 64 episodes of relapse. Relapses were treated with a 10-day course of rTMS, with an average of 4 treatment courses per patient (range, 2-10) and a mean treatment interval of 4.9 months (range, 1.5 to 24.0). About one half of the patients had a clinically significant response to repeated courses of rTMS and continued in the study. These patients had a medication-free interval of 33 months (range, 26 to 43 months) and
a mean response on the HAM-D of 64.8%. Other subjects terminated the study due to non-response after the second (n=3), third (n=1), fourth (n=2), or fifth (n=1) treatment course.

A variety of maintenance schedules are being studied. Richieri et al. used propensity-adjusted analysis of observational data and found that the group of patients who had maintenance rTMS tapered over 20 weeks (from 3 times per week to once a month) had a significantly reduced relapse rate compared with patients who had no additional treatment (37.8% vs. 81.8%).27 Connolly et al. reported that in the first 100 cases treated at their institution the response rate was 50.6% and the remission rate was 24.7%.28 At 6 months after the initial rTMS treatment, 26 of 42 patients (62%) who received tapered maintenance therapy (from 2 sessions per week for the first 3 weeks to monthly) maintained their response. In another study, patients who met criteria for partial response during either a sham–controlled or open-label phase of a prior study were tapered from rTMS and simultaneously started on maintenance antidepressant monotherapy.29 During the 24 week follow-up, 10 of 99 patients relapsed, 38 had symptom worsening, and of these 32 (84%) had symptomatic benefit with adjunctive rTMS.

Fitzgerald et al. reported a prospective open-label trial of clustered maintenance rTMS for patients with refractory depression.30 All patients had received a second successful course of rTMS following relapse, and were then treated with monthly maintenance therapy consisting of 5 rTMS treatments over a 2.5-day period (Friday evening, Saturday and Sunday). Patients were treated with maintenance therapy of the same type that they had initially received (14 high frequency to the left dorsolateral prefrontal cortex, 12 low frequency to the right dorsolateral prefrontal cortex, and 9 bilateral). The primary outcome was the mean duration until clinical relapse, addition or change of antidepressant medication, or withdrawal from maintenance treatment to pursue other treatment options. Out of 35 patients, 25 (71%) relapsed at a mean of 10.2 months (range, 2 to 48 months), which was substantially shorter than the interval (< 3 months) for relapse from the initial treatment.

A 2015 meta-analysis examined durability of the antidepressant effect of high frequency rTMS of the left DLPFC in the absence of maintenance treatment. Included were 16 double-blind sham controlled RCTs with a total of 495 patients. The range of follow-up was 1 - 16 weeks, but most studies reported follow-up of only 2 weeks. The overall effect size was small with a standardized mean difference (Cohens d) = -.48, and the effect sizes were lower in RCTs with 8-16 week follow-up (d = -.42) compared to 1 - 4 week follow-up (d = -.04). The effect size was higher when antidepressant medication was started concurrently with rTMS (5 RCTs, d = -.56) than when patients were on a stable dose of medication (9 RCTs, n = -.43) or were unmedicated (2 RCTs, d = -.26).
Alzheimer Disease

Ahmed et al. randomized 45 patients with probable Alzheimer disease to 5 sessions of bi-lateral high-frequency rTMS, bi-lateral low-frequency rTMS, or sham TMS over the dorsolateral prefrontal cortex. Thirty-two patients had mild to moderate dementia and 13 had severe dementia. There were no significant differences between groups at baseline. Measures of cortical excitability immediately after the last treatment session showed that treatment with high-frequency rTMS reduced the duration of transcallosal inhibition. At 3 months after treatment, the high-frequency rTMS group improved significantly more than the other 2 groups in standard rating scales, and subgroup analysis showed that this was due primarily to improvements in patients with mild/moderate dementia. Patients in the subgroup of mild to moderate dementia who were treated with high-frequency rTMS improved from 18.4 to 22.6 on the Mini Mental State Examination (MMSE), from 20.1 to 24.7 on the Instrumental Daily Living Activity (IADL) scale and from 5.9 to 2.6 on the Geriatric Depression Scale (GDS).

Rabey et al. reported an industry-sponsored randomized double-blind trial of rTMS with cognitive training (NeuroAD system) in 15 patients with probable mild to moderate Alzheimer’s disease. Patients received 5 sessions per week for 6 weeks over 6 different brain areas, followed by biweekly sessions for 3 months. Specific cognitive tasks were designed for the 6 targeted brain regions. These included syntax and grammar for Broca’s area, comprehension and categorization for Wernicke’s area, action naming, object naming and spatial memory tasks for the right and left dorsolateral prefrontal cortex, and spatial attention tasks for the right and left somatosensory association cortex. After 6 weeks of treatment there was an improvement in the average Alzheimer Disease Assessment Scale, cognitive subsection (ADAS-cog) score of 3.76 points in the rTMS group compared to 0.47 in the placebo group. After 4.5 months of treatment the ADAS-cog score in the rTMS group had improved by 3.52 points compared to a worsening of 0.38 in the placebo group. The Clinical Global Impression of Change improved significantly by an average of 3.57 after 6 weeks and 3.67 after 4.5 months compared to 4.25 and 4.29 in the placebo group.

Attention-Deficit/Hyperactivity Disorder

In 2012, Weaver et al. reported a randomized sham-controlled crossover study of rTMS in 9 adolescents/young adults with attention-deficit/ hyperactivity disorder (ADHD). rTMS was administered in 10 sessions over 2 weeks, with 1 week of no TMS between the active and sham phases. The clinical global impression and ADHD-IV scales improved in both conditions over the course of the study, with no significant differences between the active and sham phases.
**Bulimia Nervosa**

In 2008, Walpoth et al. reported no evidence of efficacy of rTMS in a small trial (n=14) of patients with bulimia nervosa.\(^{34}\)

**Dysphagia**

rTMS for the treatment of dysphagia following stroke has been examined in small randomized controlled trials. One study randomized 26 patients to rTMS or sham over the affected esophageal motor area of the cortex.\(^{35}\) Ten minutes of rTMS over 5 days reduced both dysphagia on the Dysphagic Outcome and Severity scale and disability measured by the Barthel Index. There was a trend for improved hand grip strength in the rTMS group. Blinded assessment showed that the effects were maintained at 1 month and 2 month follow-up. Another study randomized 30 patients with dysphagia following stroke or traumatic brain injury to high frequency rTMS, low frequency rTMS, or sham stimulation.\(^{32}\) Active or sham rTMS was administered bilaterally over the anterolateral scalp over a period of 2 weeks. Swallowing scale scores improved in both the low-frequency and sham groups. Improvement in videofluoroscopic evaluation was greater in the low frequency rTMS group than the other 2 groups. Blinding of evaluators was not described.

Study in a larger number of subjects is needed to determine the efficacy of this treatment with greater certainty.

**Epilepsy**

In 2012, Sun et al. reported a randomized double-blind controlled trial of low frequency rTMS to the epileptogenic zone for refractory partial epilepsy.\(^{37}\) Sixty patients were randomized into 2 groups; one group received 2 weeks of rTMS at 90% of resting motor threshold and the other group received rTMS at 20% of resting motor threshold. Outcomes were measured for 8 weeks after the end of treatment. With intent-to-treat analysis, high intensity rTMS resulted in a significant decrease in seizures when compared to baseline (from 8.9 per week at baseline to 1.8 per week at follow-up) and when compared to low intensity rTMS (from 8.6 at baseline to 8.4 per week at follow-up). High intensity rTMS also decreased interictal discharges (from 75.1 to 33.6 per hour) and improved ratings on the Symptom Checklist-90. These initial results are promising, but require substantiation in additional trials.
Fibromyalgia

A 2012 systematic review included 4 studies on transcranial direct current stimulation and 5 on rTMS for treatment of fibromyalgia pain. Three of the 5 trials were considered to be high quality. Four of the 5 were double-blind randomized controlled trials; the 5th included study was a case series of 4 patients who were blinded to treatment. Quantitative meta-analysis was not conducted due to variability in brain site, stimulation frequency/intensity, total number of sessions, and follow-up intervals, but 4 of the 5 studies on rTMS reported significant decreases in pain. Greater durability of pain reduction was observed with stimulation of the primary motor cortex compared to the dorsolateral prefrontal cortex.

One of the studies included in the systematic review was a small 2011 trial that was conducted in the U.S. by Short et al. Twenty patients with fibromyalgia, defined by the American College of Rheumatology criteria, were randomized to 10 sessions of left prefrontal rTMS or sham TMS along with their standard medications. At 2 weeks after treatment, there was a significant change from baseline in average visual analog scale (VAS) for pain in the rTMS group (from 5.60 to 4.41) but not in the sham-treated group (from 5.34 to 5.37). There was also a significant improvement in depression symptoms in the active group compared to baseline (from 21.8 to 14.10) but not in the sham group (from 17.6 to 16.4). There were no statistically significant differences between the groups in this small trial.

Additional study is needed to determine effective treatment parameters in a larger number of subjects and to evaluate durability of the effect.

Migraine Headache

A pivotal randomized, double blind, multi-center, sham-controlled trial was performed with the Cerena™ TMS device to demonstrate safety and effectiveness for the De Novo application. Enrolled in the study were 201 patients with a history of an aura preceding more than 30% of headaches with moderate or severe headache severity for approximately 90% of migraine attacks. Following a month baseline phase to establish the frequency and severity of migraine, patients were randomized to a treatment phase consisting of three treatments or three months, whichever occurred first. Patients were instructed to treat their migraine headache during the aura phase and to record their pain severity (0-3), severity of associated migraine symptoms (photophobia, phonophobia, nausea), presence of vomiting, and use of rescue medications at the time of treatment and at 1, 2, 24, and 48 hours after treatment. The primary endpoint was
the proportion of patients who were pain free 2 hours after treatment. Of the 201 patients enrolled, 164 recorded at least 1 treatment and 113 recorded at least 1 treatment when there was pain. Post-hoc analysis of these 113 patients showed a benefit of the device for the primary endpoint (37.74% pain free after 2 hours for Cerena™ and 16.67% for sham, \( p=0.0181 \)) and for the proportion of subjects who were pain free after 24 hours (33.96% for Cerena™ and 10% for sham, \( p=0.0025 \)). Active treatment was not inferior to sham for the proportion of subjects free of photophobia, suggesting that the device does not worsen photophobia. However, the device was not non-inferior to sham for the proportion of subjects free of nausea and phonophobia.

These results are limited by the 46% drop-out rate and post-hoc analysis. According to the FDA labeling, the device has not been demonstrated as safe or effective when treating cluster headache, chronic migraine headache, or when treating migraine headache during the aura phase. The device has not been demonstrated as effective in relieving the associated symptoms of migraine (photophobia, phonophobia, and nausea).41

**Obsessive Compulsive Disorder**

A 2013 meta-analysis included 10 small randomized controlled trials totaling 282 patients with obsessive compulsive disorder (OCD).42 Response rates of rTMS augmentation therapy were 35% for active and 13% for sham rTMS. The pooled odds ratio (OR) was 3.39 and the number needed to treat (NNT) was 5. There was no evidence of publication bias. Exploratory subgroup analysis suggested that the two most promising stimulation parameters were low frequency rTMs and non-DLPFC regions (ie, orbitofrontal cortex or supplementary motor area). Further study focusing on these stimulation parameters is needed.

**Panic Disorder**

In 2013, Mantovani et al. reported a randomized double-blind sham-controlled trial of low frequency rTMS to the right dorsolateral prefrontal cortex in 21 patients with panic disorder with comorbid major depression.43 Response was defined as a 40% or greater decrease on the panic disorder severity scale (PDSS) and a 50% or greater decrease on the HAM-D. After 4 weeks of treatment, the response rate for panic was 50% with active rTMS and 8% with sham. There was no significant difference in the response rate for depressive symptoms (25% active rTMS vs. 8% for sham). After an additional 4 weeks of open-label treatment, the response rate was 67% for panic and 50% for depressive symptoms. Five of 12 responders returned for 6-month follow-up and showed sustained improvement.
Parkinson Disease

A systematic review from 2009 included 10 randomized controlled trials with a total of 275 patients with Parkinson disease.\textsuperscript{44} Seven of the studies were double-blind, one was not blinded and 2 of the studies did not specify whether the raters were blinded. In studies that used high frequency rTMS there was a significant improvement on the Unified Parkinson’s Disease Rating Scale (UPDRS) with a moderate effect size of -0.58. For low frequency rTMS the results were heterogeneous and did not significantly reduce the UPDRS. The analyzed studies varied in outcomes reported, rTMS protocol, patient selection criteria, demographics, stages of Parkinson disease and duration of follow-up, which ranged from immediate to 16 weeks after treatment.

In 2012, Benninger et al. reported a randomized double-blind sham-controlled trial of brief (6 sec) very high frequency (50 Hz) rTMS over the motor cortex in 26 patients with mild to moderate Parkinson disease.\textsuperscript{45} Eight sessions of 50 Hz rTMS did not improve gait, bradykinesia, or global and motor scores on the UPDRS compared to the sham-treated group. Activities of daily living were significantly improved a day after the intervention, but the effect was no longer evident at 1 month after treatment. Functional status and self-reported well-being were not affected by the treatment. No adverse effects of the very high frequency stimulation were identified.

Another study from 2012 randomized 20 patients with Parkinson disease to 12 brief sessions (6 min) of high frequency (5-Hz) rTMS or sham rTMS over the leg area of the motor cortex followed by treadmill training.\textsuperscript{46} Blinded evaluation showed a significant effect of rTMS combined with treadmill training on neurophysiological measures, and change in fast walking speed and the timed up and go task. Mean treadmill speed improved to a similar extent in the active and sham rTMS groups.

A 2013 exploratory multicenter double-blind trial randomized 106 patients to 8 weeks of 1 Hz rTMS, 10 Hz rTMS, or sham stimulation over the supplementary motor area.\textsuperscript{47} At 9 weeks all groups showed a similar amount of improvement. At the 20-week follow-up only the 1 Hz group showed a significant improvement (6.84 points) in the primary outcome measure, the UPDRS part III. There was no significant improvement in other outcome measures.

A meta-analysis from 2015 included 20 sham-controlled RCTs with a total of 470 patients with Parkinson disease. Sample sizes ranged from 8 to 102. The total effect size of rTMS on Unified Parkinson’s Disease Rating Scale (UPDRS) part III score was 0.46, which is considered a small to medium effect size, and the mean change in the UPDRS-III score (-6.42) was considered to be a clinically important difference. The greatest effect on motor symptoms was from high frequency
rTMS over the primary motor cortex (standardized mean difference [SMD] of 0.77, p<0.001) and low-frequency rTMS over other frontal regions (SMD: 0.50, p=0.008). High frequency rTMS at other frontal regions and low frequency rTMS over the primary motor cortex did not have a statistically significant benefit.

Additional study with a larger number of subjects and longer follow-up is needed to determine if rTMS improves motor symptoms in patients with Parkinson disease.

**Postpartum Depression**

Myczkowski et al. conducted a double-blind sham-controlled study of 14 patients with postpartum depression randomized to 20 sessions of active or sham rTMS over the left dorsolateral prefrontal cortex. A positive response to treatment was defined as a reduction of at least 30% in the HAM-D and Edinburgh Postnatal Depression Scale (EPDS). At 2 weeks after the end of treatment, the active rTMS group showed significant improvements in the HAM-D, Global Assessment Scale, Clinical Global Impression and Social Adjustment Scale. The difference in the EPDS (reduction of 39.4% vs. 6.2% for sham) did not reach statistical significance in this small study, and there were marginal cognitive and social improvements. In addition, results were presented as mean values, rather than by the proportion of patients who showed clinically meaningful improvement.

**Posttraumatic Stress Disorder**

The efficacy of rTMS for posttraumatic stress disorder (PTSD) has been examined in several small randomized controlled trials.

A 2004 study randomized 24 patients with PTSD to 10 sessions of low frequency (1 Hz), high frequency (10 Hz) or sham rTMS over the right dorsolateral prefrontal cortex. Blinded assessment 2 weeks after the intervention found that high frequency rTMS improved the self-reported PTSD checklist (PCL) by 29.3%, the clinician evaluation on the Treatment Outcome PTSD scale by 39.0%, the HAM-D by 25.9%, and the Hamilton Anxiety Rating Scale by 44.1%. Scores for the sham and low-frequency group were not significantly improved.

In 2012, Watts et al. reported a double-blind trial with 20 patients randomized to low frequency rTMS or sham over the right dorsolateral prefrontal cortex. Blinded evaluation at the end of treatment showed clinically significant improvements in the Clinician Administered PTSD Scale (CAPS) and the PCL compared with sham. Depressive and anxiety symptoms also improved in
the rTMS group. Six of the 10 rTMS patients showed a degradation of symptoms between the immediate post-treatment assessment and the 2-month post-treatment follow-up.

In another double-blind trial, 30 patients with PTSD were randomized to deep, high frequency rTMS after brief exposure to a script of the traumatic event, rTMS after a script of a non-traumatic event, or sham stimulation after a brief script of the traumatic event. Patients received 3 treatment sessions per week for 4 weeks, and response was defined as a 50% or greater improvement in CAPS score. Intent-to-treat analysis showed a significant improvement in the total CAPS score in the exposure + stimulation group (24.3) compared to rTMS alone (7.9) or traumatic exposure with sham rTMS (9.1). The greatest improvement was in the intrusive component of the CAPS scale. Heart rate responses to the traumatic script were also reduced over the 4 weeks of treatment. The proportion of patients who showed a response to treatment was not reported and the durability of the response was not assessed.

**Conclusions**

Several small randomized controlled trials have reported improvement of PTSD with rTMS over the right dorsolateral cortex. Results of high frequency versus low frequency stimulation are conflicting, and durability of the response has not been assessed. Additional study is needed.

**Schizophrenia**

The largest area of TMS research outside of depressive disorders appears to be treatment of auditory hallucinations in schizophrenia resistant to pharmacotherapy. In 2011, TEC published an Assessment of TMS as an adjunct treatment for schizophrenia. Five meta-analyses were reviewed, along with randomized controlled trials (RCTs) in which measurements were carried out beyond the treatment period. A meta-analysis of the effect of TMS on positive symptoms of schizophrenia (hallucinations, delusions, and disorganized speech and behavior) did not find a significant effect of TMS. Four meta-analyses that looked specifically at auditory hallucinations showed a significant effect of TMS. It was noted that outcomes were evaluated at the end of treatment, and the durability of the effect is unknown. The Assessment concluded that the available evidence is insufficient to demonstrate that TMS is effective in the treatment of schizophrenia.

A 2012 meta-analysis included 17 randomized double blind sham-controlled trials (n=337) of the effect of rTMS on auditory hallucinations. When measured at the end of treatment, the mean effect size of rTMS directed at the left temporoparietal area was 0.40 (moderate) and the
effect size of rTMS directed at all brain regions was 0.33 (small). For the 5 trials that examined outcomes of rTMS one month after treatment, the effect was no longer significant.

Blumberger et al. examined the efficacy of priming stimulation (6 Hz) prior to low frequency stimulation (1 Hz) of Heschl’s gyrus within the left temporoparietal cortex. Fifty-four patients with medication resistant auditory hallucinations were randomized to receive 20 sessions of left-sided stimulation, priming, or sham rTMS. Response rates on the Psychotic Symptoms Rating Scale did not differ between the 3 treatment groups. A small (n=18) double-blind randomized sham-controlled trial from 2012 found no significant effect of deep rTMS with an H1 coil on auditory hallucinations.

A 2015 Cochrane review included 41 studies with a total of 1,473 participants. Based on very low-quality evidence, there was a significant benefit of temporoparietal TMS compared to sham for global state (7 RCTs) and positive symptoms (5 RCTs). The evidence on cognitive state was equivocal. For prefrontal rTMS compared to sham, the evidence on global state and cognitive state was of very low quality and equivocal. The authors concluded that there is insufficient evidence to support or refute the use of TMS to treat symptoms of schizophrenia, and although there is some evidence to suggest that temporoparietal TMS may improve certain symptoms such as auditory hallucinations and positive symptoms of schizophrenia, the results were not robust enough to be unequivocal.

**Conclusions**

The evidence on rTMS for the treatment of auditory hallucinations in schizophrenia consists of a number of small randomized controlled trials. Evidence to date shows small to moderate effects on hallucinations when measured at the end of treatment, but evidence suggests that the effect is not durable.

**Stroke**

A 2013 Cochrane review included 19 trials with a total of 588 participants on the effect of transcranial magnetic stimulation for improving function after stroke. The 2 largest trials showed that rTMS was not associated with a significant improvement in function. The review concluded that current evidence does not support the routine use of rTMS for the treatment of stroke.
Hsu et al. reported a meta-analysis of the effect of rTMS on upper limb motor function in patients with stroke in 2012. 57 Eighteen randomized-controlled trials with a total of 392 patients were included in the meta-analysis. Most of the studies were double blind (n=11) or single blind (n=3). Eight studies applied low frequency (1 Hz) rTMS over the unaffected hemisphere, 5 applied high frequency (5 Hz) rTMS over the affected hemisphere, and 2 used both low- and high-frequency stimulation. Outcomes included kinematic motion analyses (5 trials), hand grip (2 trials), and the Wolf Motor Function Test (2 trials). Meta-analysis of results showed a moderate effect size (0.55) for rTMS on motor outcome, with a greater effect size of rTMS in patients with subcortical stroke (mean effect size, 0.73) compared to non-specified lesion sites (mean effect size, 0.45), and for studies applying low frequency rTMS (mean effect size, 0.69) compared to high frequency rTMS (effect size, 0.41). Effect size of 0.5 or greater was considered to be clinically meaningful.

In 2012, Seniow et al. reported a randomized double-blind sham-controlled pilot study of low frequency rTMS (1 Hz at 90% of resting motor threshold for 30 min) to the contralesional motor cortex combined with physiotherapy in patients with moderate upper extremity hemiparesis following stroke. 58 Power analysis indicated that a sample size of 129 patients would be required to detect changes in functional motor ability, but only 40 patients met eligibility criteria over the 4 years of the study. Blinded analysis showed no significant difference in hand function or level of neurological deficit between active or sham rTMS when measured either immediately after the 3-week intervention or at 3-month follow-up.

A 2015 meta-analysis included 4 RCTs on rTMS over the right pars triangularis for patients (N=137) with aphasia after stroke. All of the studies used double-blinding, but therapists were not blinded. Every study used a different outcome measure, and the sample sizes were small (range from 12 to 40). Meta-analysis showed a medium effect size for naming (p=0.004), a trend for a benefit on repetition (p=0.08), and no significant benefit for comprehension (p=0.18). Additional study in a larger number of patients is needed to determine with greater certainty the effect of this treatment on aphasia after stroke.

**Conclusions**

Evidence consists of a number of randomized controlled trials and a meta-analysis of the effect of rTMS on recovery from stroke. Results are conflicting, and efficacy may depend on the location of the stroke and frequency of the rTMS. Additional study is needed to determine whether rTMS facilitates standard physiotherapy in patients with stroke.
Other Psychiatric/Neurologic Disorders

For other psychiatric/neurologic conditions, the evidence is insufficient to determine whether rTMS leads to improved outcomes. The available clinical trials are small and report mixed results for a variety of conditions other than depression. There are no large, high-quality trials for any of these other conditions. Therefore, rTMS is considered investigational for other psychiatric/neurologic conditions.

2012 Update

Re-examination of the George et al. study\(^8\) reveals the following additional information: This was an NIMH-sponsored, industry-independent trial. As such, it was the first major published study of rTMS that was not industry-sponsored and therefore free of potential industry bias. This was also the first major published study of rTMS with the sham treatment modified so that the experience of actual rTMS was duplicated, thereby creating a significantly more reliable sham effect than in the previous published trials. Although the response rate for rTMS subjects in Phase I was only 14.1%, the statistical effect size is significant and comparable to the best medication efficacy data. In addition, in the Phase II follow-up, although open-label, the response rate increased to 30%. The retention rate of 88% was higher than in most situations of actual clinical practice with antidepressant medication. The patient sample consisted of individuals who had either failed 3 or more research-quality antidepressant medication trials, or had tried and were intolerant to at least 3 antidepressant medications. In patients who have failed 2 medication trials, open-label studies (the STAR*D trials) have shown that remission rates with another medication or with augmentation are less than 20%, and in patients with 3 failed medication trials, remission rates with another medication trial are 10% to 20%. Thus, the 30% remission rate in Phase II of this trial compares favorably with continued medication trials, and demonstrates effectiveness for treatment-resistant depression that is exceeded only by electroconvulsive therapy (ECT), which remains the most effective treatment for treatment-resistant depression. This study indicates that rTMS is an effective antidepressant treatment for Major Depression in patients who do not respond to or cannot tolerate antidepressant medications.

A study by Ray et al.\(^64\) that was also not industry-funded, in which none of the investigators had any ties to industry, and which also utilized realistic sham treatment, demonstrated remission in 75% of patients receiving actual rTMS as an add-on to antidepressant medication compared to 10% of patients who received sham rTMS. This study also included patients with psychotic depression, and in that population, 87.5% of patients receiving actual rTMS as an add-on to
Antidepressant medication achieved remission as compared to 7.7% of patients who received sham treatment. The study did lack rater blinding, which may have allowed for some degree of rater bias, but the effect size was substantial and would still be quite large even if rater bias could be accounted for.

Two more recent, naturalistic studies have demonstrated the effectiveness of TMS in real world practice settings without the constraints of research-based patient selection criteria. Carpenter et al. studied the effectiveness of TMS with 339 consecutive patients at 42 different practice sites (academic and community). Patients had failed at least one antidepressant trial (average 2.5). The clinician-assessed response rate was 58% and remission rate was 37.1%. The patient-assessed response rate was 41.5%-56.4% and remission rate was 26.5%-28.7%. These rates are greater than those in earlier academic center studies. Although, as is typical of naturalistic studies, the study lacked sham treatment (placebo) and blinded rater assessment, it approximated real-world clinical practices to a much greater extent than prior studies. Connolly et al. conducted a retrospective chart review of 100 consecutive TMS patients at an academic medical center. Although done at an academic center, this study approximated real-world practice because patients were treated without applying research criteria. The patient population had failed an average of 3.4 adequate antidepressant trials in the current depressive episode. The clinician-measured response rate was 50.6% and the remission rate was 24.7%. This study and the Carpenter et al study, in spite of the absence of placebo controls and blinded rating, demonstrate real-world effectiveness of TMS in the treatment of Major Depression that has not responded to adequate trials of antidepressant medication.

Summary

Although questions still need to be answered about TMS, including the optimal length of treatment and the usefulness of maintenance treatment, the most recent studies demonstrate efficacy and real-world effectiveness of TMS in the treatment of unipolar Major Depression and psychotic depression (ie, Major Depression with psychotic features). Antidepressant medication remains the biological treatment of first choice for Major Depression. ECT continues to be the most effective treatment for treatment-resistant depression, but the high incidence of functionally-impairing adverse cognitive effects renders ECT undesirable in many cases. In addition, there is a cohort of patients who have failed or cannot tolerate antidepressant medications and ECT. For those patients, with the possible exception of major chest surgery and its attendant potential complications (ie, for a Vagus Nerve stimulator implant, for which the effectiveness data is weak), TMS is the only treatment option that remains, and that stands between possible relief of depression and continued indefinite suffering. That rationale, coupled
with the results of the most recent studies, and with the knowledge that continued antidepressant medication trials after 3-4 trials have a high failure rate, leads to the conclusion that TMS is a reasonable and appropriate next intervention after 3 failed medication trials plus a failed ECT trial, or after 4 failed medication trials.

2015 Update

Evidence for the efficacy and effectiveness of TMS for adolescents is limited to anecdotal case reports and inadequately-sized studies. There are no large, high-quality trials of TMS for adolescents. Therefore, TMS is considered to be generally investigative for adolescent, though exceptions may be appropriate on a case-by-case basis for adolescents who have no other viable treatment options.

Alternate types of TMS that are under investigation include synchronized TMS, low field magnetic stimulation, and theta burst stimulation. There are no large, high-quality trials of these types of TMS, and they are therefore considered to be investigative.

2016 Update

See individual sections for 2016 literature and position statement updates.

Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov in August 2017 identified over 300 ongoing trials on rTMS.

Practice Guidelines and Position Statements

American Psychiatric Association (APA)

The APA 2010 practice guidelines for the treatment of patients with major depressive disorder states that treatment in the acute phase should be aimed at inducing remission of the major depressive episode and achieving a full return to the patient’s baseline level of functioning [I, Recommended with substantial clinical confidence]. Acute phase treatment may include pharmacotherapy, depression-focused psychotherapy, the combination of medications and
psychotherapy, or other somatic therapies such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or light therapy. A number of strategies are available when a change in the treatment plan seems necessary. Transdermal selegiline, a relatively selective MAO B inhibitor with fewer dietary and medication restrictions, or transcranial magnetic stimulation could also be considered [II, Recommended with moderate clinical confidence].

**American Academy of Child and Adolescent Psychiatry**

In 2013, the American Academy of Child and Adolescent Psychiatry (AACP) Committee on Quality Issues published practice parameters for the assessment and treatment of children and adolescents with tic disorders. AACP does not recommend repetitive transcranial magnetic stimulation, citing the limited evidence regarding safety, ethics, and long term impact on development.

**National Institute for Health and Care Excellence (NICE)**

In 2007 the National Institute for Health and Care Excellence (NICE) published an Interventional Procedure Guideline (IPG) 242 which stated that current evidence suggests no major safety concerns for the use of TMS in the treatment of depression. There was uncertainty related to the clinical efficacy of TMS which may depend on a number of factors such as higher intensity, greater frequency, bilateral application, and/or longer treatment durations than have appeared in evidence to date. TMS should be performed in research studies designed to evaluate these factors. The opinion was repeated in the NICE 2009 Clinical Guideline (CG) 90.

NICE guidance in 2006 on the management of bipolar disorder in adults, children and adolescents in primary and secondary care states that TMS should not be routinely used for acute depressive episodes in people with bipolar disorder. The guidance states that TMS is not of proven efficacy for bipolar disorder and that when compared with sham TMS the participants receiving sham treatment had lower endpoint mania symptom scores.

In December 2015, NICE updated its Interventional Procedure Guidelines [IPG542] which has the following recommendations:

- The evidence on repetitive transcranial magnetic stimulation for depression shows no major safety concerns. The evidence on its efficacy in the short term is adequate, although the clinical response is variable. Repetitive transcranial magnetic stimulation for depression may be used with normal arrangements for clinical governance and audit.
During the consent process, clinicians should, in particular, inform patients about the other treatment options available, and make sure that patients understand the possibility the procedure may not give them benefit.

NICE encourages publication of further evidence on patient selection, details of the precise type and regime of stimulation used, the use of maintenance treatment and long term outcomes.

**American Academy of Neurology (AAN)**

2006 Practice guidelines on the evaluation and treatment of depression, psychosis, and dementia in Parkinson disease from the AAN concluded that there is insufficient evidence to support or refute the efficacy of TMS or electroconvulsive therapy (ECT) in the treatment of depression associated with Parkinson disease (Level U; Data inadequate or conflicting given current knowledge, treatment is unproven).63

**Canadian Network for Mood and Anxiety Treatments (CANMAT)**

The CANMAT updated their clinical guidelines on neurostimulation therapies for the management of major depressive disorder in adults.64 The evidence reviewed supported ECT as a first-line treatment under specific circumstances; when used in patients who have failed to respond to one or more adequate antidepressant medication trials, ECT response rates have been estimated to be 50-60%. The guidelines considered rTMS to be a safe and well-tolerated treatment, with no evidence of cognitive impairment. Based on the 2008 meta-analysis by Lam et al.70, response (25%) and remission (17%) rates were found to be greater than sham but lower than for other interventions for TRD, leading to a recommendation for rTMS as a second-line treatment. The guidelines indicated that there is a major gap in the evidence base regarding maintenance rTMS, as only one open-label case series was identified.

**Medicare National Coverage**

There is a national coverage determination (NCD) and local coverage determinations that cover left prefrontal rTMS for patients diagnosed with severe Major Depression (single or recurrent episode) as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and meet several other criteria.
Regulatory Status

Devices for transcranial stimulation have received clearance by the U.S. Food and Drug Administration (FDA) for diagnostic uses include the following:

- NeoPulse (Neuronetics, Atlanta, GA) received approval in Canada, Israel and the United States as a therapy for depression. Initially examined by the FDA under a traditional 510(k) application, the NeoPulse, now known as NeuroStar® TMS, received clearance for marketing as a “De Novo” device in 2008.

- NeuroStar® TMS is indicated for the treatment of patients with depression who have failed one 6-week course of antidepressant medication.

**Note:** An FDA advisory panel met in January 2007 to determine if the risk to benefit profile for the NeoPulse was comparable to the risk to benefit profile of predicate electroconvulsive therapy (ECT) devices. The panel was not asked for a recommendation regarding the regulatory determination of substantial equivalence for this 510(k) submission. Materials presented at the Neurological Devices Panel meeting are posted online at: [https://wayback.archive-it.org/7993/20170405055025/https://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4273b1_14-Bibliography-510kAppendix24.pdf](https://wayback.archive-it.org/7993/20170405055025/https://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4273b1_14-Bibliography-510kAppendix24.pdf) Accessed November 2018.

FDA approved devices for transcranial stimulation treatment of major depression disorder include but may not be limited to the following:

- For standard repetitive TMS: NeuroStar® TMS (formerly known as NeoPulse); MagPro “R” series stimulators; MagVita TMS Therapy system; Magstim Rapid Therapy System

- For deep TMS: Brainsway™ H-Coil Deep TMS device

The Brainsway™ H-Coil Deep TMS device (Brainsway Ltd.) received FDA clearance in 2013. This device is indicated for the treatment of depression in patients who have failed to respond to antidepressant medications in their current episode of depression and is a broader indication than that of the NeuroStar® TMS, which specifies the failure of one course of antidepressant medication (product code: OBP).

Other TMS devices not FDA approved for the treatment of depression and other psychiatric disorders:
The Cerena™ TMS device (Eneura Therapeutics) received De Novo marketing clearance in 2013 for the acute treatment of pain associated with migraine headache with aura. Warnings, precautions, and contraindications include the following:

- The device is only intended for use by patients experiencing the onset of pain associated with a migraine headache with aura.
- The device should not be used on headaches due to underlying pathology or trauma.
- The device should not be used for medication overuse headaches.
- The device has not been demonstrated as safe or effective when treating cluster headache or chronic migraine headache.
- The device has not been shown to be effective when treating during the aura phase.
- The device has not been demonstrated as effective in relieving the associated symptoms of migraine (photophobia, phonophobia, and nausea).
- Safety and effectiveness have not been established in pregnant women, children under the age of 18, and adults over the age of 65.

The De Novo 510(k) review process allows novel products with moderate or low risk profiles and without predicates which would ordinarily require premarket approval as a class III device to be down-classified in an expedited manner and brought to market with a special control as a class II device.

References

4. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Transcranial magnetic stimulation for depression. TEC Assessments 2011; Volume 26, Tab 3.


### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDI</td>
<td>Beck Depression Inventory</td>
</tr>
<tr>
<td>DLFPC</td>
<td>Dorsolateral prefrontal cortex</td>
</tr>
<tr>
<td>ECT</td>
<td>Electroconvulsive therapy</td>
</tr>
<tr>
<td>HAM-D</td>
<td>Hamilton Depression Rating Scale</td>
</tr>
<tr>
<td>MADRS</td>
<td>Montgomery-Asberg Depression Rating Scale</td>
</tr>
<tr>
<td>MT</td>
<td>Motor threshold</td>
</tr>
<tr>
<td>rTMS</td>
<td>Repetitive transcranial magnetic stimulation</td>
</tr>
<tr>
<td>TRD</td>
<td>Treatment-resistant depression</td>
</tr>
</tbody>
</table>

### History

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/14/13</td>
<td>New policy. Policy replaces 2.01.50 which is deleted. Previously considered investigational for all indications, policy statement created to consider TMS medically necessary for treatment resistant major depression when certain criteria are met. Added code 296.2x.</td>
</tr>
<tr>
<td>02/13/13</td>
<td>Replace policy. Added code 296.3x. Added literature review on multiple conditions: rTMS maintenance therapy, Alzheimer’s, ADHS, Dysphagia, Epilepsy, Fibromyalgia, Panic Disorder, Parkinson Disease. Postpartum Depression, Posttraumatic Stress Disorder and Stroke.</td>
</tr>
<tr>
<td>07/25/13</td>
<td>Update Related Policies. Add 8.01.39.</td>
</tr>
<tr>
<td>06/19/14</td>
<td>Annual Review. Policy updated with an additional criteria of “bona-fide contraindication to ECT on the first medically necessary policy statement. An additional medically necessary policy for treatment of bipolar depression (Major Depression as a component of Bipolar Disorder or Schizoaffective Disorder) when criteria are met (failed medication trials as outlined and a positive clinical response to a previous course of treatment with TMS). References reordered and</td>
</tr>
<tr>
<td>07/14/14</td>
<td>Interim Update. For treatment of bipolar depression (Major Depression as a component of Bipolar Disorder or Schizoaffective Disorder), medically necessary policy criterion “failure of trials of 4 antidepressant medications, or 3 antidepressant medications plus ECT, as indicated above for Major Depression, except that all trials must have reached the point of adequate dose and duration or intolerable effects without the emergence of mania or hypomania” removed.</td>
</tr>
<tr>
<td>02/25/15</td>
<td>Annual Review. Under Major Depressive Disorder policy statement removed criteria about failure of 3 medication trials or ECT trial contraindications/intolerance/poor</td>
</tr>
<tr>
<td>Date</td>
<td>Comments</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>response. Policy updated with literature review through October, 2014; references 9, 15, 17, 25, 27, 36, 48, 52-53, 55 added; others renumbered/removed. Policy statement criteria removed as noted.</td>
</tr>
<tr>
<td>04/14/15</td>
<td>Interim Update. Medically necessary policy statement addressing Major Depressive Disorder updated with an additional criterion: failure of at least 3 different antidepressant medication trials, from at least 2 different classes, plus failure with the addition of an augmenting agent to at least one of the antidepressants. Policy Guidelines section updated with the removal of pregnancy as a contraindication to TMS; notation made of repeat course of TMS due to relapse to be determined on a case-by-case basis.</td>
</tr>
<tr>
<td>08/31/15</td>
<td>Update Related Policies. Remove 8.01.39 as it was archived.</td>
</tr>
<tr>
<td>11/10/15</td>
<td>Interim Update. Policy statements clarified in application to those 18 years an older. Policy section updated to types of TMS which are considered medically necessary (standard repetitive transcranial magnetic stimulation and deep transcranial magnetic stimulation only) versus investigational (all other types).</td>
</tr>
<tr>
<td>04/01/16</td>
<td>Annual Review, approved March 8, 2016. Policy updated with literature review; several references added. NICE recommendations updated. Clinical Trials section added. No change to the policy statement.</td>
</tr>
<tr>
<td>10/01/16</td>
<td>Interim Update, approved September 16, 2016 Updated Types of TMS and coding section.</td>
</tr>
<tr>
<td>09/01/17</td>
<td>Annual Review, approved August 22, 2017. Policy moved to new format. No changes to policy statement, minor grammatical updates.</td>
</tr>
<tr>
<td>10/01/17</td>
<td>Interim Review, approved September 21, 2017. Clarifications added that medical necessity is determined case-by-case for more than the indicated number of sessions with either treatment planning, cortical mapping, and initial motor threshold determination (CPT code 90867), or with motor threshold re-determination (CPT code 90869). Also added that an abbreviated repeat course of TMS is also known as a “mini-intensive.”</td>
</tr>
<tr>
<td>12/01/18</td>
<td>Annual Review, approved November 21, 2018. No changes to policy statement.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2018 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to
the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination is Against the Law

LifeWise Health Plan of Washington complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. LifeWise does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

LifeWise:
• Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
• Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that LifeWise has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-6396, Fax 425-918-5592, TTY 800-842-5357
Email AppealsDepartmentInquiries@LifeWiseHealth.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
Office for Civil Rights Complaint Portal, available at
800-592-6804 (TTY: 800-842-5357)

Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through LifeWise Health Plan of Washington. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help pay your medical bills. You have the right to get this information and help in your language at no cost. Call 800-592-6804 (TTY: 800-842-5357).

Français (French):

Deutsche (German):

Italiano (Italian):

中文 (Chinese):
本通知有重要的訊息。本通知可能有關於您透過 LifeWise Health Plan of Washington 提交的申請或保險的重要訊息。本通知內可能有重要日期。您可能需要在截止日期之前採取行動。以保留您的健康保險或者費用補貼。您有權利免費以您的母語得到本訊息和幫助。請撥電話 800-592-6804 (TTY: 800-842-5357).